Previous 10 | Next 10 |
Even with significant success over the past four years, DexCom (NASDAQ: DXCM) appears set to continue its growth in 2022 and beyond. In this segment of "The Earnings Show" on Motley Fool Live , recorded on Feb. 11 , Fool contributors Taylor Carmichael and Brian Withers discu...
In this clip from "The Rank" on Motley Fool Live, recorded on Feb. 7 , Motley Fool contributors Taylor Carmichael and Jason Hall discuss their thoughts on DexCom (NASDAQ:DXCM) and share the reasons why it makes for a strong stock pick despite challenges. Taylor Carmi...
Image source: The Motley Fool. DexCom (NASDAQ: DXCM) Q4 2021 Earnings Call Feb 10, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: DexCom (DXCM) Q4 2021 Earnings Call Transcript
DexCom (NASDAQ:DXCM) is trading ~3% lower in the post-market after the med-tech company reported a mixed performance with its Q4 2021 results and set its 2022 guidance below expectation. Despite an earnings miss, the quarterly revenue met the consensus even as the growth momentum sl...
DexCom press release (NASDAQ:DXCM): Q4 Non-GAAP EPS of $0.68 misses by $0.17. Revenue of $698.2M (+22.7% Y/Y) in-line. U.S. revenue growth of 15% and international revenue growth of 54% on a reported basis. International revenue growth was 41% on an organic basis. FY22 Guidance: Rev...
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2021. Fourth Quarter 2021 Financial Highlights: Revenue grew 23% versus the same quarter of the prior year to $698.2 million on a reported basi...
While the market hasn't been in the best shape so far in 2022, that doesn't mean these woes will continue for the rest of the year. And even if they do, history tells us that the market eventually recovers from corrections. These otherwise stressful events create opportunities to buy shares...
Updating its Tactical U.S. Equity Themes, UBS introduced a new theme of Selloff Opporutunities. The screen "highlights a list of companies that look attractive following recent market volatility." "We believe some stocks have been unfairly punished in the sell-off," UBS' theme team wrote in a...
Dexcom (NASDAQ:DXCM) said people with diabetes who are under 18 years of age and require ongoing use of insulin or insulin pump therapy are eligible for public coverage of Dexcom G6 CGM System through Alberta Health. The company said Alberta joins five other jurisdictions in providing pu...
Dexcom CGM use is proven to improve glycemic control 1,2 and can reduce the risk of costly diabetes-related complications compared to fingerstick monitoring. 3 Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM), an...
News, Short Squeeze, Breakout and More Instantly...
2024-07-04 10:00:00 ET Growth-oriented investors have experienced a bit of a roller-coaster ride over the past few years. Many companies in the "growth stock" category were struggling just two years ago, but in the bull market we are now experiencing, they're delivering very different resul...
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2024 financial results after market close on Thursday, July 25, 2024. Management will hold a conference call to review the company's second quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the...